The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of gut dysbiosis biomarkers and peripheral thyroid hormones conversion in patients with (pts) advanced lung cancer.
 
Adele Bonato
No Relationships to Disclose
 
Lorenzo Belluomini
Speakers' Bureau - AstraZeneca/MedImmune; Roche
Research Funding - Bristol Myers Squibb
Travel, Accommodations, Expenses - Astrazeneca; Novartis; Takeda
 
Carolina Alves Costa Silva
No Relationships to Disclose
 
Marine Fidelle
No Relationships to Disclose
 
Roxanne Birebent
No Relationships to Disclose
 
Federica Gattazzo
No Relationships to Disclose
 
Claudia Parisi
No Relationships to Disclose
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca; Boehringer ingelheim; Bristol-Myers Squibb; Genmab; Janssen Oncology; Merck; MSD Oncology; OSE Immunotherapeutics; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Inivata; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
Pernelle Lavaud
No Relationships to Disclose
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Mihaela Aldea
Consulting or Advisory Role - Viatris
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Sandoz
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)
Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Fotios Loupakis
Employment - 3trees Healthcare; AstraZeneca; Menarini
 
Laurence Zitvogel
Leadership - EverImmune; Hookipa Biotech; Transgene
Stock and Other Ownership Interests - EverImmune
Honoraria - EverImmune; Hookipa Biotech; Transgene
Consulting or Advisory Role - EverImmune; German Cancer Aid; Hookipa Biotech; Pierre Fabre; Transgene
Research Funding - 9 Meters Biopharma; Biomérieux; Daiichi Sankyo; EverImmune; Pileje; Transgene
Patents, Royalties, Other Intellectual Property - EverImmune
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
Other Relationship - Seerave Foundation
(OPTIONAL) Uncompensated Relationships - MaaT Pharma
 
Lisa Derosa
No Relationships to Disclose